Bengaluru, Sept. 16 -- The pharma stock gained after its subsidiary launched the first FDA-approved generics of phenylpropanolamine and furosemide tablets for veterinary use. Strong Q1FY26 results, robust pipeline, and steady guidance with 30+ launches and >26% margins highlight sustained growth momentum across domestic and international markets

The shares of the prominent pharmaceutical company gained up to 1 percent in today's trading session after the company's subsidiary launched the first FDA-approved generic of phenylpropanolamine hydrochloride tablets.

With a market capitalization of Rs 1,04,462.18 crore, the shares of Zydus Lifesciences Ltd were trading at Rs 1038.15 per share, increasing around 0.28 percent as compared to the p...